Short Interest in Genprex, Inc. (NASDAQ:GNPX) Increases By 5.2%

Genprex, Inc. (NASDAQ:GNPX) was the recipient of a significant increase in short interest during the month of October. As of October 15th, there was short interest totalling 85,200 shares, an increase of 5.2% from the September 30th total of 81,000 shares. Based on an average trading volume of 8,350,000 shares, the short-interest ratio is currently 0.0 days. Currently, 3.5% of the shares of the stock are short sold.

Genprex Trading Down 4.4 %

Genprex stock opened at $2.15 on Friday. The business’s 50-day moving average price is $0.79 and its two-hundred day moving average price is $1.59. Genprex has a 12-month low of $0.28 and a 12-month high of $14.80.

Genprex (NASDAQ:GNPX) last released its quarterly earnings data on Friday, August 9th. The company reported ($3.00) EPS for the quarter, missing the consensus estimate of ($2.30) by ($0.70). As a group, equities research analysts forecast that Genprex will post -5.7 EPS for the current year.

Hedge Funds Weigh In On Genprex

An institutional investor recently raised its position in Genprex stock. Armistice Capital LLC lifted its position in shares of Genprex, Inc. (NASDAQ:GNPX) by 122.7% during the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 218,000 shares of the company’s stock after purchasing an additional 120,132 shares during the quarter. Armistice Capital LLC owned about 10.39% of Genprex worth $411,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 14.05% of the company’s stock.

Genprex Company Profile

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.